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Renal cyclooxygenase-2 in obese Zucker (fatty) rats.
Background. Cyclooxygenase (COX) isoforms, COX-1 and
COX-2, are involved in production of prostanoids in the kid-
ney. Increases in renal COX-2 expression have been implicated
in the pathophysiology of progressive renal injury, including
type 1 diabetes. Thromboxane A2 (TxA2) has been suggested
as the key mediator of these effects resulting in up-regulation of
prosclerotic cytokines and extracellular matrix proteins. Unlike
type 1 diabetes, renal COX has not been studied in models of
type 2 diabetes.
Methods. Renal cortical COX protein expression, and urinary
excretion of stable metabolites of prostaglandin E2 (PGE2) and
TxA2, in association with metabolic parameters, were deter-
mined in 4-and 12-week-old Zucker fatty rats (fa/fa rat) (ZDF4
and ZDF12), a model of type 2 diabetes, and in age-matched
littermates with no metabolic defect (Zucker lean) (ZL4 and
ZL12).
Results. Western blotting revealed increased COX-2 expres-
sion in ZDF4 as compared to ZL4 (245 ± 130%) (P < 0.05). This
increase in COX-2 was even more apparent in 12-week-old ZDF
rats (650 ± 120%) (P < 0.01). All groups of rats demonstrated
COX-2–positive cells in typical cortical localizations [macula
densa, thick ascending loop of Henle (TALH)]. In contrast to
COX-2, COX-1 expression was 30% lower in ZDF12. These
changes in COX expression were associated with enhanced uri-
nary excretion of prostanoids, in parallel with the development
of metabolic abnormalities. Moreover, increases in prostanoid
excretion in ZDF12 were in part reduced by wortmannin (100
lg/kg), used as inhibitor of insulin signaling.
Conclusion. Renal cortical COX-2 protein expression and
function were increased in ZDF rats, as compared to controls,
whereas COX-1 exhibited opposite regulation. The changes in
COX-2 paralleled metabolic abnormalities, and were at least in
part a four consequence of hyperinsulinemia. These abnormal-
ities may play a role in renal pathophysiology in this model of
type 2 diabetes.
The role of cyclooxygenase (COX) metabolites of
arachidonic acid in the development of renal alterations,
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and in the pathogenesis of diabetic nephropathy in type 1
diabetes, has been suggested in a number of clinical stud-
ies [1–3], as well as in experimental models of diabetes
[4–9].
Two isoforms of COX have been identified, COX-1 and
COX-2. COX-1 is constitutively expressed in most tissues
and performs housekeeping functions in the vascular sys-
tem. In the normal adult kidney, COX-1 has been local-
ized to arteries and arterioles, glomeruli, and collecting
ducts [10, 11]. In contrast, COX-2 operates as an inducible
enzyme with low or undetectable levels in most tissues,
and its expression can be markedly increased by a number
of inflammatory, mitogenic, and physical stimuli [12, 13].
Although considered to be an inducible enzyme, COX-2
is constitutively expressed in occasional renal cells of the
thick ascending loop of Henle (TALH) and in the region
of the macula densa of the rat kidney, and in podocytes
in the human kidney [11, 14, 15].
Increased COX-2 expression and activity has been de-
scribed in several models of progressive renal disease, in-
cluding models of type 1 diabetes [8, 9]. Long-term studies
have demonstrated beneficial effects of selective COX-2
inhibitors in these experimental conditions on the devel-
opment of proteinuria and renal structural damage [8,
16, 17] [abstract; Komers R, J Am Soc Nephrol 13:166A,
2002]. These renoprotective effects could be attributable
to inhibition of thromboxane A2 (TxA2) production and
consequent beneficial effects on mRNA expression of
transforming growth factor-b (TGF-b), and molecular
markers of glomerular injury, such as type III type IV col-
lagen [8, 17]. Consequently, COX-2–derived metabolites
are likely to play a role in the development of diabetic
nephropathy.
Nephropathy is also a major problem in type 2 diabetes
[18]. Various animal models have been reported that
could help to elucidate the pathophysiology of nephropa-
thy in type 2 diabetes [19]. One such model is the
Zucker diabetic fatty rat (fa/fa) (ZDF) [20]. These rats are
metabolically well characterized: an autosomal-recessive
mutation of the fa gene, encoding the leptin receptor,
results in hyperphagia, obesity, and hyperlipidemia [21].
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Similar to patients with type 2 diabetes, ZDF rats display
insulin resistance, hyperinsulinemia, and impaired glu-
cose tolerance, and slowly progressive increases in blood
glucose levels [22].
ZDF rats develop progressive albuminuria and
glomerulosclerosis later in the course of nephropathy
[23]. However, unlike the streptozotocin (STZ) diabetic
rats, renal COX-2 expression and function have not been
studied in models of type 2 diabetes.
To address this issue, we determined renal protein ex-
pression, localization, and regulation of COX-2, together
with expression of COX-1, in 4- and 12-week-old ZDF
fa/fa rats and in age-matched control Zucker lean rats
(ZL) that do not develop the diabetic phenotype.
METHODS
ZL and ZDF rat were obtained from Charles River
(Sulzfeld, Germany). Renal cortical expression of COX
isoforms, immunohistochemical localization of COX-
2, and urinary excretion of stable metabolites of
prostaglandin E2 (PGE2) and TxA2, together with
metabolic and renal parameters were studied in six male
ZDF rats at the ages of 4 and 12 weeks, and in six age-
matched ZL rats as controls.
To further explore possible role of hyperinsuline-
mia in regulation of renal cortical COX-2 in ZDF rats,
additional groups of 12-week-old ZDF and ZL were
administered with intraperitoneal injection of the phos-
phatidyl inositol-3-kinase (PI3K) inhibitor wortmannin
[24][100 lg/kg body weight in 15% dimethyl sulfoxide
(DMSO)] (Cell Signaling Technology, Inc., Beverly, MA,
USA) or with vehicle (15% DMSO). Immediately af-
ter wortmannin or vehicle administration, the rats (N =
5 in each group) were placed into metabolic cages
to obtain timed urine samples for analysis of urinary
excretion of PGE2 and TxB2. General physical and
metabolic parameters were measured in separate groups
of wortmannin-or vehicle-treated ZL and ZDF (N = 5
in each group), sacrificed 90 minutes after injection. In
previous in vivo studies conducted by Gao et al [25],
substantially lower dose of wortmannin (15 lg/kg body
weight) injected intravenously blocked insulin-induced
increases in Akt activity, and inhibited beneficial effects
of insulin on apoptosis in a rat model of myocardial
infarction.
All experiments were carried out with the approval
of, and in accordance with the regulations of, the Insti-
tutional Animal Care and Use Committee of the Insti-
tute for Clinical and Experimental Medicine. The animals
were housed with a light-dark cycle of 12 hours each, and
with free access to food (standard chow) and water. The
blood and tissues were harvested without previous food
restriction.
Immunoblotting and immunohistochemistry
The rats were sacrificed with cervical dislocation and
the blood was collected into chilled tubes for determi-
nations of glucose levels and plasma insulin concentra-
tions. After collection of blood samples, the kidneys were
exposed via midabdominal incision, removed, decapsu-
lated, divided into cortical and medullary portions, and
snap frozen in liquid nitrogen for Western blot analysis.
The half of the left kidney was immersed in 10% formalin
for immunohistochemistry.
To obtain whole cell homogenates, kidney cortices
were homogenized in RIPA buffer containing 50 mmol/L
Tris, 150 mmol/L NaCl, 0.5% sodium deoxycholate, 0.1%
sodium dodecyl sulfate (SDS), and 1.0% Triton X-100,
and protease inhibitors (leupeptin 20 lg/mL and benza-
midine 20 lg/mL), and centrifuged at 12000 × g for 30
minutes at 4◦C. The resulting supernatant was aliquoted
and saved at −70◦C until analysis. Total protein content in
fractions was determined by BCA analysis (Pierce Chem-
ical Co., Rockford, IL, USA).
Immunoblotting was performed as previously de-
scribed [9]. In brief, denatured proteins were separated
through an SDS-polyacrylamide gel and transferred to
polyvinylidine difluoride (PVDF) membranes (Bio-Rad
Laboratories, Hercules, CA, USA). Membranes were
washed and then blocked overnight with Tris-buffered
saline, plus 0.05% Tween-20 (TBS-T) containing 5%
nonfat dry milk. Following blocking, membranes were
again washed, and incubated overnight with rabbit poly-
clonal antimurine COX-2 or COX-1 antisera (Cayman
Chemical, Ann Arbor, MI, USA) diluted 1:800 in TBS-
T. Immunodetection was accomplished by incubating
membranes with a goat antirabbit-IgG secondary an-
tibody conjugated with horseradish peroxidase (HRP)
for 45 minutes (1:100,000) (Pierce Chemical Co.) in
TBS-T containing 5% nonfat dry milk. Visualization
was performed with enhanced chemiluminiscence (ECL)
Western-blotting kit (Supersignal West Dura) (Pierce
Chemical Co.) according to the manufacturer’s instruc-
tions. Resultant films (Eastman Kodak Co., Rochester,
NY, USA) (Scientific Imaging Systems, New Haven, CT,
USA) were scanned using a flatbed scanner and images
analyzed with NIH Image software. The membranes were
then stripped, reblocked, and reincubated for 1 hour at
room temperature with goat antiactin antibody (Santa
Cruz Biotechnology, Santa Cruz, CA, USA), followed by
45-minute incubation with antigoat-IgG secondary anti-
body conjugated with HRP (1:4000) (Santa Cruz Biotech-
nology), and reaction with ECL as described above.
For immunohistochemical analysis, the fixed kidneys
were processed as previously described [9]. The fixed
kidney halves were dehydrated through a graded se-
ries of ethanols, embedded in paraffin, sectioned at 4
lm thickness, and placed onto glass slides. The same
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Table 1. Physical and renal characteristics in 4-week-old and 12-week-old lean Zucker (ZL) and fatty diabetic Zucker (ZDF) rats
Right kidney Right kidney weight/100 g Creatinine Urinary protein
Number Body weight g weight g body weight clearance mL/min excretion lg/min
ZL 4 weeks 5 103 ± 2 0.43 ± 0.01 0.42 ± 0.01 ND ND
ZDF 4 weeks 6 131 ± 6a 0.51 ± 0.01b 0.40 ± 0.02 ND ND
ZL 12 weeks 5 358 ± 9 1.13 ± 0.05 0.31 ± 0.01 0.93 ± 0.13 5.6 ± 0.9
ZDF 12 weeks 6 538 ± 25b 1.30 ± 0.04b 0.24 ± 0.01‡ 0.92 ± 0.10 13.6 ± 3.0c
aP < 0.01; bP < 0.001 vs. ZL of the same age; cP < 0.05.
antibody as described above was used for immunohis-
tochemical detection of COX-2 in ZDF and ZL rats. Sec-
tions were deparaffinized, and pretreated by steaming in
10% Citra buffer (BioGenex, San Ramon, CA, USA).
After blocking, the slides were incubated overnight at
4◦C with primary antibody (diluted 1:100) or with the
same concentration of nonimmune mouse IgG as a con-
trol. Endogenous peroxidase activity was blocked with
3% H2O2 solution in methanol. The primary antibody
was localized using the Vectastain ABC-Elite peroxidase
detection system (Vector Laboratories, Burlingame, CA,
USA). This was followed by reaction with diaminoben-
zidine (DAB) as chromogen and counterstaining with
hematoxylin (Sigma Chemical Co., St. Louis, MO, USA).
Sections of each diabetic kidney were processed in par-
allel with appropriate control tissue.
Urinary excretion of COX metabolites
Within 5 days prior to sacrifice, the 12-week-old ZL
and ZDF rats, and 12-week-old wortmannin- or vehicle-
treated ZL and ZDF rats underwent timed urine col-
lections in metabolic cages with free access to food and
water. The urine was collected in volumetric tubes im-
mersed in a mixture of ice and dry ice. After completion
of collections, the urine was immediately stored at −70◦C
and kept frozen until further analysis. Urinary PGE2 and
its metabolites, and urinary concentrations of TxB2, a sta-
ble metabolite of TxA2, were analyzed using enzyme im-
munoassay (EIA) (Cayman Chemicals, Ann Arbor, MI,
USA) according to the manufacturer’s instructions.
Analytical methods
Blood glucose levels were measured by the glucose
oxidase assay (Pliva-Lachema, Czech Republic). Serum
insulin concentrations were measured using a rat in-
sulin RIA kit (Amersham Biosciences, Piscataway, NJ,
USA). Serum triglyceride concentrations were deter-
mined by standard enzymatic methods (Pliva-Lachema),
and serum nonesterified fatty acids (NEFA) were mea-
sured using an acyl-coenzymeA oxidase–based col-
orimetric kit (Roche Diagnostics, Basel, Switzerland).
Plasma and urinary creatinine were measured using com-
mercially available kit (Pliva-Lachema). Urinary pro-
tein concentrations were measured spectrophotometri-
cally after reaction with perchloric acid (Pliva-Lachema).
Statistical analysis
Data are expressed as mean ± SEM. All analyses were
performed by analysis of variance (ANOVA) followed by
the Scheffe´ test. Differences in responses to treatments
between control and diabetic rats were tested by two-
way repeated measures ANOVA, using Statview SE and
Graphics software (Brainpower, Calabasas, CA, USA).
A P value of less than 0.05 was viewed as statistically
significant.
RESULTS
General physical, renal, and metabolic parameters
in ZL and ZDF rats
General physical and renal parameters in ZL and ZDF
rats are summarized in Table 1. ZDF rats demonstrated
increased body and renal weight gain, although the kid-
ney/body weight ratio was not different in 4-week-old
ZL and ZDF, and even decreased in 12-week-old ZDF
as compared to ZL of the same age. There were no dif-
ferences in creatinine clearance between the 12-week-old
ZL and ZDF groups.
However, urinary protein excretion was slightly, but
significantly increased in 12-week-old ZDF rats com-
pared with ZL.
Metabolic parameters in 4- and 12-week-old rats are
shown in Table 2. ZDF rats demonstrated progressive in-
creases in plasma insulin concentrations in parallel with
increased serum triglyercide and NEFA concentrations.
Blood glucose levels were slightly but significantly in-
creased in both age groups of ZDF as compared to ZL.
Protein expression of COX isoforms and
prostanoid excretion
As shown in Figure 1A, ZDF rats demonstrated in-
creases in renal cortical COX-2 protein expression as
compared to ZL rats. The difference in COX-2 expres-
sion between the ZL and ZDF groups was more promi-
nent with increasing age. In all groups of rats, immunore-
active COX-2 was localized in typical localizations in
macula densa cells, and in the TALH. In ZL, COX-2
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Table 2. Metabolic characteristics in lean Zucker (ZL) and fatty diabetic Zucker (ZDF) rats
Blood Nonesterified fatty
Plasma insulin nmol/L glucose mmol/L Triglyceride mmol/L acids mmol/L
[nmol/L] [mmol/L] [mmol/L] [mmol/L]
ZL 4 weeks 0.40 ± 0.04 4.0 ± 0.1 0.6 ± 0.1 ND
ZDF 4 weeks 0.74 ± 0.07a 5.5 ± 0.6b 1.4 ± 0.1a ND
ZL 12 weeks 0.48 ± 0.09 5.3 ± 0.1 0.9 ± 0.1 0.43 ± 0.02
ZDF 12 weeks 1.81 ± 0.19c 6.7 ± 0.3‡ 4.2 ± 0.4c 0.54 ± 0.02c
aP < 0.01; bP < 0.05; cP < 0.001 vs. ZL of the same age.
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Fig. 1. Renal cortical cyclooxygenase (COX)-2 and COX-1 expression
in Zucker lean (ZL) and fatty diabetic rats (ZDF). (A) Increased COX-
2 expression was apparent already in 4-week-old ZDF rats (ZDF4) and
further increased in 12-week-old ZDF rats (ZDF12) as compared to
age-matched lean counterparts (ZL4 and ZL12). The upper panels show
representative blots. (B) There were no significant differences in COX-
1 expression between the 4-week-old ZDF and ZL rats. In contrast,
COX-1 expression was lower in 12-week-old ZDF rats as compared to
age-matched lean counterparts. The insets show representative blots.
∗P < 0.05 vs. ZL; †P < 0.01 vs. ZL.
immunoreactivity in both locations was found in occa-
sional cells, whereas ZDF rats demonstrated clusters of
COX-2–positive cells (Fig. 2). In contrast to COX-2, there
were no significant differences in COX-1 expression be-
tween ZL and ZDF rats at age 4 weeks (Fig. 1B). More-
over, in 12-week-old ZDF rats, COX-1 expression was
lower than in their age-matched ZL counterparts (P <
0.05).
To assess the impact of observed changes in protein ex-
pression of renal COX isoforms on production of COX-
derived metabolites, further studies determined urinary
excretion of PGE2 and TxB2, a stable metabolite of TxA2,
in 12-week-old rats. Urinary excretion of both metabo-
lites was increased in ZDF as compared to ZL rats
(Fig. 3).
Acute effects of wortmannin on PGE2 and TxB2
excretion
Further experiments focused on the possible role of
hyperinsulinemia in modulation of COX activity in ZDF
rats. Additional groups of 12-week-old ZL and ZDF
rats were administered with wortmannin or with vehicle.
Wortmannin acts as an inhibitor of PI3K, an important
intermediate in insulin signaling [26]. The differences in
physical and metabolic parameters between the vehicle-
treated ZL and ZDF rats (Table 3) as well as the differ-
ences in PGE2 and TxB2 excretion (Fig. 4) between the
vehicle-treated ZL and ZDF rats were similar as in the
previous protocol. Wortmannin had no effect on these
parameters in ZL. In contrast, wortmannin-treated ZDF
rats demonstrated significantly lower TxB2 excretion and
a similar trend in PGE2 excretion (Fig. 4), as compared
to their vehicle-treated counterparts. These changes were
associated with an increase in plasma triglyceride and a
decrease in NEFA concentrations (Table 3).
DISCUSSION
In the present studies, ZDF rats, studied as a model
of type 2 diabetes, demonstrated a progressive increase
in COX-2 expression in the renal cortex as compared to
lean controls. In contrast to COX-2, COX-1 expression
was lower in 12-week-old ZDF. These changes in expres-
sion of COX isoforms in ZDF rats were associated with
increased urinary excretion of both PGE and TxB2, de-
termined as a stable metabolite of TxA2. The changes in
expression and activity of COX isoforms in ZDF rats were
associated with metabolic abnormalities characteristic of
the insulin-resistant state, increased kidney weight, and
mild proteinuria; however, the kidney/body weight ratio
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Fig. 2. Renal cortical immunohistochemical localization of cyclooxy-
genase (COX)-2 in Zucker lean (ZL) (A) and fatty diabetic rats (ZDF)
(C). Representative images in 12-week-old rats are shown. Both in ZL
and ZDF rats, COX-2 was localized in the cells of macula densa and
in thin ascending limb of Henle (TALH) (arrows, 200×). (B and D)
Control adjacent sections incubated with nonimmune IgG.
in 12-week-old animals was lower than in lean controls
due to marked obesity.
Our present findings demonstrate another model of
progressive renal injury that is associated with increased
cortical COX-2 expression and activity. Considering the
documented role of COX-2–derived metabolites in the
pathophysiology of progressive renal disease, these ob-
servations suggest that COX-2 might be involved in the
pathophysiology of renal disease in the ZDF rat. Evolu-
tion of nephropathy in ZDF has been well described. Ex-
tensive studies by Kasiske et al [23] and Coimbra et al [27]
have shown that the first detectable changes in glomeru-
lar morphology suggestive of glomerulosclerosis and sig-
nificant proteinuria occur at about 4 to 5 months of age,
whereas more subtle changes characterized by glomeru-
lar mesangial matrix expansion and albuminuria occur by
14 weeks of age. Thus, similar to findings in some other
models of progressive glomerulosclerosis, such as the rat
remnant kidney model [28], fawn-hooded hypertensive
rats [29], or type 1 diabetic nephropathy [8, 9], increased
renal expression of COX-2 and enhanced generation of
prostanoids in ZDF rats precedes the development of
glomerulosclerosis. Furthermore, in the present studies
it coincided with early development of proteinuria.
An increase in renal cortical COX-2 expression in ZDF
rats corresponds to previous reports by our group as well
as by other investigators, suggesting marked increases in
renal COX-2 expression and function in models of type 1
diabetes [8, 9]. However, there are striking differences be-
tween the metabolic environments associated with COX-
2 up-regulation in the present and in previous studies.
Unlike the studies in type 1 diabetes, changes in COX-2
expression in ZDF were not closely associated with hy-
perglycemia, since at 12 weeks of age, ZDF rats demon-
strated only mild hyperglycemia, and their younger
counterparts had blood glucose levels still within the
normoglycemic range. Therefore, some other factors
must contribute to COX dysregulation in the ZDF.
The increase in COX-2 expression, as observed in ZDF
rats, paralleled the development of insulin resistance
and metabolic abnormalities characterized by progres-
sive obesity, hyperinsulinemia, serum triglyceride, and
NEFA concentrations. Therefore, a progressive increase
in COX-2 expression is likely linked to the development
of the metabolic syndrome.
Hyperinsulinemia is one of the most striking
metabolic/hormonal abnormalities in the ZDF. There-
fore, we embarked on further studies to explore the role
of this factor in the enhanced prostanoid excretion in this
model of type 2 diabetes. To inhibit the major insulin sig-
naling pathway, the rats were administered the inhibitor
of PI3K, wortmannin. This intervention significantly re-
duced TxB2 excretion in ZDF rats, albeit the change in
PGE did not reach statistical significance. These findings,
together with the lack of effect of wortmannin in ZL rats,
suggest that enhanced COX-2 activity in ZDF is in part
insulin-dependent. Although PI3K is not activated only
by insulin, but by a number of other factors, hyperin-
sulinemia is such a prominent feature in ZDF rats that
effects of wortmannin could be attributable to inhibition
of insulin signaling.
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Fig. 3. Urinary excretion of stable metabo-
lites of prostaglandin E (PGE) and thrombox-
ane A2 (TxA2) in 12-week-old fatty diabetic
Zucker (ZDF) and lean Zucker (ZL) rats as
controls. ZDF demonstrated increased excre-
tion of both COX metabolites as compared to
ZL. ∗P < 0.05.
Table 3. Physical and metabolic characteristics in vehicle- and wortmannin-treated lean Zucker (ZL) and fatty diabetic Zucker (ZDF) rats
Right kidney Right kidney weight/100 g Blood Nonesterified fatty
Number Body weight g weight g body weight glucose mmol/L Triglyceride mmol/L acids mmol/L
ZL vehicle 5 345 ± 11 1.06 ± 0.06 0.31 ± 0.01 4.4 ± 0.1 0.67 ± 0.10 0.30 ± 0.04
ZDF vehicle 5 508 ± 22a 1.23 ± 0.04b 0.24 ± 0.01a 5.8 ± 0.2a 2.82 ± 0.12c 0.50 ± 0.04c
ZL wortmannin 5 355 ± 10 1.05 ± 0.03 0.30 ± 0.01 4.6 ± 0.1 0.59 ± 0.07 0.24 ± 0.04
ZDF wortmannin 5 516 ± 17a 1.17 ± 0.05b 0.23 ± 0.01a 6.1 ± 0.2a 4.52 ± 0.47c 0.29 ± 0.03d
aP < 0.001 vs. ZL; bP < 0.05; cP < 0.01; dP < 0.01 vs. ZDF-vehicle.
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Fig. 4. Urinary excretion of stable metabo-
lites of prostaglandin E (PGE) and throm-
boxane A2 (TxA2) in 12-week-old fatty di-
abetic Zucker (ZDF) and lean Zucker (ZL)
treated with wortmannin or with a vehi-
cle. Vehicle-treated ZDF (ZDF-veh) demon-
strated increased excretion of both cyclooxy-
genase (COX) metabolites as compared to ZL
(ZL-veh). Wortmannintreated ZDF (ZDF-
WORT) rats demonstrated significantly lower
TxB2 excretion as compared to vehicle-
treated counterparts. In contrast to ZDF,
wortmannin induced no changes in TxB2 ex-
cretion in ZL (ZL-WORT). ∗P < 0.05 vs. ZL.
Analysis of metabolic parameters in wortmannin-
treated ZDF also showed marked reduction in plasma
NEFA concentrations, together with higher triglyceride
concentrations. Detailed discussion of this phenomenon
is beyond the scope of this paper, but these changes could
be related to decreased activity of hormone-sensitive
lipoprotein lipase in adipose tissue [30]. Furthermore,
these observations could be considered as additional
proof of effective PI3K inhibition by wortmannin admin-
istered at a given dose. Since NEFA act as precursors
for synthesis of arachidonic acid [31], and therefore, as
precursors of a spectrum of COX metabolites, the reduc-
tion in NEFA levels observed in response to wortmannin
administration in ZDF rats could also contribute to at-
tenuation in TxB2 excretion. Thus, in addition to insulin,
enhanced COX-2 activity in ZDF rats could be also at-
tributable to increased NEFA.
Although the experiments assessing the acute effects
wortmannin on COX enzymatic activity suggest the link
between the hormonal and metabolic characteristics of
metabolic syndrome and renal COX dysregulation, it
should be noted that this interpretation is based on
just a few measurements of urinary prostaglandins and
metabolic parameters. Therefore, these data should be
viewed as exploratory and supportive. To provide con-
clusive evidence, future studies should focus on measure-
ments of COX-2 activity and expression, together with
indicators of renal injury in models of type 2 diabetes,
after long-term modulation of these metabolic/hormonal
risk factors.
COX-1 was not the major focus of the present stud-
ies. However, our finding of decreased expression of
this isoform in 12-week-old ZDF rats may have patho-
physiologic significance. Considering the documented
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localization of this isoform in collecting ducts [11], it has
been hypothesized that COX-1–derived metabolites are
involved in natriuresis. For example, pressure natriuretic
responses were inhibited by indomethacin, but not by a
selective COX-2 inhibitor [32]. Reduction in COX-1 ex-
pression in ZDF rats could contribute to later develop-
ment of hypertension in this model by decreased natri-
uretic responses.
Lessons derived from studies focusing on renal COX-2
regulation may provide additional clues for determina-
tion of factors characteristic both for the metabolic syn-
drome and for modulation of COX-2 expression in the
renal cortex. COX-2 expression and function in macula
densa cells is stimulated by decreased sodium chloride
concentration in tubular fluid. In particular, chloride ion
tubular concentrations seem to be important for COX-2
regulation. Insulin is a potent stimulator of chloride re-
absorption up-stream from macula densa [33, 34]. There-
fore, progressive hyperinsulinemia in ZDF rats may be
associated with changes in ionic content of tubular fluid
sensed by macula densa cells leading to up-regulation of
COX-2. In this context, Schnyder et al [35] have recently
provided persuasive evidence that insulin signaling path-
ways involved in insulin-induced sodium reabsorption in
proximal tubular cells are not affected by insulin resis-
tance.
Previous studies by Vora et al [36] have suggested
that a significant proportion of ZDF rats develop hy-
dronephrosis later in the course of nephropathy. This
phenomenon may interfere with identification of renal
pathophysiologic mechanisms specific for metabolic syn-
drome. Theoretically, development of hydronephrosis
could trigger processes that would lead to COX-2 up-
regulation. Our present studies were deliberately per-
formed at early stages of the disease, when both age
groups of ZDF do not display hydronephrosis.
CONCLUSION
We report complex changes in renal cortical expression
of COX isoforms in ZDF rats as compared to lean con-
trols. These changes were characterized by a progressive
increase in COX-2; COX-1 expression was lower in 12-
week-old ZDF rats. These changes in expression of COX
isoforms in the ZDF rats were associated with increased
urinary excretion of both PGE and TxB2, determined
as a stable metabolite of TxA2. The changes in COX-
2 expression and activity paralleled the development of
metabolic abnormalities characteristic of insulin resistant
states. Further experiments with wortmannin suggested
the link between hormonal/metabolic factors character-
istic for type 2 diabetes (hyperinsulinemia and increased
plasma NEFA concentrations) and COX-2 up-regulation
and enhanced prostanoid excretion. With respect to the
documented roles of COX in the regulation of kidney
function and in renal pathophysiology, the observed al-
terations in COX expression and function could con-
tribute to the later development of nephropathy in this
model of type 2 diabetes. Furthermore, the data provide
a rationale for studies of additional metabolic/hormonal
mechanisms operating in the pathophysiology of diabetic
nephropathy.
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